Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GVAX Clear all
Completed Phase 1 Interventional

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

NCT01966289
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
CY, GVAX, SGI-110
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 20, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

NCT02648282
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX Pancreatic Cancer Vaccine, Pembrolizumab, SBRT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 20, 2026, 2:50 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

NCT01088789
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, Cyclophosphamide Pill, GVAX Pancreas Vaccine
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 20, 2026, 2:50 PM EDT
Terminated Phase 3 Interventional

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00089856
View directory record Official record
Conditions
Prostate Cancer
Interventions
Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone)
Biological · Drug
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older · Male only
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
83
States / cities
Alabaster, Alabama • Anchorage, Alaska • Glendale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2008 · Synced Sep 20, 2026, 2:50 PM EDT
Terminated Phase 3 Interventional

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

NCT00133224
View directory record Official record
Conditions
Prostate Cancer
Interventions
Immunotherapy allogeneic GM-CSF secreting cellular vaccine, Chemotherapy (docetaxel and prednisone)
Biological · Drug
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older · Male only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
43
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Loma Linda, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Sep 20, 2026, 2:50 PM EDT
Not listed Phase 1Phase 2 Interventional

GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

NCT00122005
View directory record Official record
Conditions
Prostate Cancer
Interventions
GM-CSF gene transduced allogeneic vaccine GVAX
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 23, 2009 · Synced Sep 20, 2026, 2:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

NCT01696877
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma in Situ
Interventions
degarelix acetate, Cyclophosphamide, GVAX
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 20, 2026, 2:50 PM EDT
Completed Not applicable Interventional

GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies

NCT00426205
View directory record Official record
Conditions
Myelodysplastic Syndrome RAEB-I or RAEB-II, Refractory Acute Myeloid Leukemia, Refractory CML Myeloid Blast Crisis
Interventions
GM-CSF secreting leukemia vaccine
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 20, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

NCT01896869
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ipilimumab, Vaccine, FOLFIRINOX
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 20, 2026, 2:50 PM EDT
Completed Phase 1Phase 2 Interventional

Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

NCT00140348
View directory record Official record
Conditions
Prostate Cancer
Interventions
Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Biological
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
12
States / cities
Laguna Woods, California • San Francisco, California • Tarzana, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2007 · Synced Sep 20, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

NCT02981524
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
CY, GVAX, Pembrolizumab
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 20, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

NCT03161379
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine, Stereotactic Body Radiation (SBRT)
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 20, 2026, 2:50 PM EDT
Active, not recruiting Phase 2 Interventional

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

NCT02451982
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX pancreatic cancer, Nivolumab, Urelumab, BMS-986253
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 20, 2026, 2:50 PM EDT